Biohaven Ltd. (BHVN) SEC Filings & Earnings Calls

Regulatory risk remains: FDA may extend review, request additional info, or issue complete response letter; advisory committee outcome uncertain.

“The FDA may extend the review period, including if it determines that information submitted during the review constitutes a major amendment, may request additional information, or may issue a complete response letter.” · word for word

Dependence on Ono's development and commercialization efforts in the licensed territory; potential termination if Ono elects not to continue after stability tests.

“If Ono elects not to continue the program after receipt of specified stability test results... the License Agreement will terminate and the milestone achievement payment will not become payable.” · word for word

FDA partial clinical hold on BHV-7000 due to insufficient nonclinical data on a metabolite, pausing new enrollment. Risk of program delay or failure if metabolite findings are relevant to humans.

“FDA instructed the Company to pause new enrollment until additional clarifying nonclinical studies are completed, and issued a partial clinical hold letter on September 4, 2026” · word for word

Execution risk in development and commercialization of Kv7 platform

“Agreement involves development, manufacturing, and commercialization; regulatory and market acceptance risks inherent in CNS drug development.”

Clinical trial risk: pivotal studies may fail to replicate early positive data.

“Phase 3 studies for BHV-1300 and BHV-1400 are ongoing; early data may not predict final outcomes.”

Going concern covenant risk on notes payable

“In the event that by the reporting deadline of March 1, 2027, our audited financial statements for the year ended December 31, 2026 or any year thereafter for the term of the agreement, are subject to any qualification, emphasis of matter or statement as to “going concern” or scope of audit, subject to certain exceptions, we would be in breach of our financi”

Dependence on future financing

“We may not be able to obtain financing on acceptable terms, or at all.” · word for word

No revenue from product sales

“To date, we have not generated any revenue from product sales, and we do not expect to generate any revenue from the sale of products in the near future.” · word for word

No material risk identified from this routine board appointment.

“Standard director appointment with no unusual arrangements or transactions.”

Low risk; transition is planned and retains key scientific leadership in a part-time role.

“Mutual agreement; no related party transactions; no arrangements with other persons.”

Clinical-stage risk remains; Phase 3 trials not yet initiated; safety profile appears favorable but limited data.

“Most AEs mild and self-resolving; no discontinuations; no serious or severe AEs.”

Potential dilution from future ATM sales

“Up to $350 million of common shares may be sold at market prices”

Going concern risk from debt covenant

“In the event that by the reporting deadline of March 2, 2026, our audited financial statements for the year ended December 31, 2025 or any year thereafter for the term of the agreement, are subject to any qualification, emphasis of matter or statement as to 'going concern' or scope of audit, subject to certain exceptions, we would be in breach of our financi” · word for word

Clinical-stage company with no approved products; all value depends on pipeline success.

“No financial metrics disclosed; company is pre-revenue.”

FDA CRL for troriluzole NDA

“In November 2025, we received a Complete Response Letter (CRL) for the NDA seeking approval of troriluzole for SCA.”

EMA MAA withdrawal for troriluzole

“In March 2025, we decided to withdraw the troriluzole MAA in the EU for the treatment of adult patients with SCA.”

Reliance on key pipeline programs

“In the fourth quarter of 2025, we initiated strategic portfolio and cost-optimization measures to prioritize three key, late-stage, clinical programs that we believe have the greatest potential for value generation.”

Clinical-stage company with no approved products; all value depends on pipeline success.

“No financial metrics disclosed; company is pre-revenue.”

FDA CRL for troriluzole NDA

“In November 2025, we received a Complete Response Letter (CRL) for the NDA seeking approval of troriluzole for SCA.” · word for word

EMA MAA withdrawal for troriluzole

“In March 2025, we decided to withdraw the troriluzole MAA in the EU for the treatment of adult patients with SCA.” · word for word

Reliance on key pipeline programs

“In the fourth quarter of 2025, we initiated strategic portfolio and cost-optimization measures to prioritize three key, late-stage, clinical programs that we believe have the greatest potential for value generation.” · word for word

Clinical trial risk for opakalim

“We expect to report topline results from RISE 3 in the second half of 2026.” · word for word

Clinical trial risk for taldefgrobep

“Biohaven initiated a Phase 2 study of taldefgrobep in the management of obesity in the fourth quarter of 2025 and expects to report topline results in 2026.” · word for word

Clinical and regulatory risks inherent in biotech pipeline.

“Forward-looking statements regarding clinical trials and regulatory approvals.”

Dilution risk from large block issuance.

“12,500,000 common shares at $10.00 per share”

Dilution risk from large equity offering

“Issuance of 26.8M shares at $7.50, representing significant dilution to existing shareholders.”

Restructuring execution risk: pausing/halting programs may impair pipeline value and future revenue potential.

“Restructuring of business priorities and optimizing resource allocation may result in either pause, delay or halting of non-priority programs.” · word for word

Regulatory risk: SCA CRL appeal process with FDA may not succeed, impacting VYGLXIA program.

“We requested a Type A meeting with FDA as part of initiating an appeal process for the SCA CRL.” · word for word

Cash burn risk: net loss of $173.4M per quarter implies ~1.5 years of runway at current cash level.

“Net loss for Q3 2025 of $173.4 million; cash $263.8 million.”

Regulatory setback for troriluzole

“In November 2025, we received a Complete Response Letter ("CRL") for the NDA seeking approval of troriluzole for SCA.” · word for word

Clinical trial failure in bipolar disorder

“Opakalim did not statistically differentiate from the comparator arm on the primary efficacy endpoint of improvement from Baseline to Day 21 on the YMRS.” · word for word

Going concern risk from debt covenant

“In the event that by the reporting deadline of March 2, 2026, our audited financial statements for the year ended December 31, 2025 or any year thereafter for the term of the agreement, are subject to any qualification, emphasis of matter or statement as to 'going concern' or scope of audit, subject to certain exceptions, we would be in breach of our financi” · word for word